期刊
FRONTIERS IN NUTRITION
卷 10, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fnut.2023.1104169
关键词
coronary artery disease; astaxanthin; lipid profile; glycemic indices; inflammation
The study analyzed the effects of Astaxanthin (AX) supplementation on cardiometabolic risk factors in patients with coronary artery disease (CAD). The results showed that AX supplementation did not significantly affect body composition, glycemic indices, TNF-alpha, and Sirtuin1 levels. However, it did lead to a significant reduction in total cholesterol and LDL-C levels. More clinical investigations are needed to establish conclusive findings.
Background: Atherosclerosis can develop as a result of an increase in oxidative stress and concurrently rising levels of inflammation. Astaxanthin (AX), a red fat-soluble pigment classified as a xanthophyll, may be able to prevent the vascular damage induced by free radicals and the activation of inflammatory signaling pathways. The objective of the current study is to assess the effects of AX supplementation on cardiometabolic risk factors in individuals with coronary artery disease (CAD). Methods: This randomized double-blind placebo-controlled clinical trial was conducted among 50 CAD patients. Participants were randomly allocated into two groups to intake either AX supplements (12 mg/day) or placebo for 8 weeks. Lipid profile, glycemic parameters, anthropometric indices, body composition, Siruin1 and TNF-alpha levels were measured at baseline and after 8 weeks. Results: Body composition, glycemic indices, serum levels of TNF-alpha, Sirtuin1 did not differ substantially between the AX and placebo groups (p > 0.05). The data of AX group showed significant reduction in total cholesterol (-14.95 +/- 33.57 mg/dl, p < 0.05) and LDL-C (-14.64 +/- 28.27 mg/dl, p < 0.05). However, TG and HDL-C levels could not be affected through AX supplementation .Conclusion: Our results suggest that AX supplementation play a beneficial role in reducing some components of lipid profile levels. However, further clinical investigations in CAD patients are required to obtain more conclusive findings.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据